A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)

PURPOSE: Preclinical and clinical data have shown promise in using antiangiogenic agents to treat malignant pleural mesothelioma (MPM). We conducted this phase II study to evaluate the efficacy and toxicity of single‐agent pazopanib in patients with MPM. MATERIALS AND METHODS: Patients with MPM who...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Parikh, Kaushal, Mandrekar, Sumithra J., Allen‐Ziegler, Katie, Esplin, Brandt, Tan, Angelina D., Marchello, Benjamin, Adjei, Alex A., Molina, Julian R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288653/
https://ncbi.nlm.nih.gov/pubmed/31872928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0574
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados